For: | Borzio M, Dionigi E, Parisi G, Raguzzi I, Sacco R. Management of hepatocellular carcinoma in the elderly. World J Hepatol 2015; 7(11): 1521-1529 [PMID: 26085911 DOI: 10.4254/wjh.v7.i11.1521] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v7/i11/1521.htm |
Number | Citing Articles |
1 |
Francesca Romana Ponziani, Giulia Gibiino, Antonio Gasbarrini. Surgical Management of Elderly Patients. 2018; : 335 doi: 10.1007/978-3-319-60861-7_23
|
2 |
Hiroko Naganuma, Hideaki Ishida. Hepatocellular Carcinoma in Non-Fibrotic Liver: A Narrative Review. Diagnostics 2023; 13(22): 3426 doi: 10.3390/diagnostics13223426
|
3 |
Nages Nagaratnam, Kujan Nagaratnam, Gary Cheuk. Geriatric Diseases. 2018; : 217 doi: 10.1007/978-3-319-33434-9_24
|
4 |
Eric Francois, Ludovic Evesque. Encyclopedia of Gerontology and Population Aging. 2021; : 1 doi: 10.1007/978-3-319-69892-2_777-1
|
5 |
Christian Ziemann, Jonas Roller, Markus M. Malter, Kira Keller, Otto Kollmar, Matthias Glanemann, Michael D. Menger, Jens Sperling. Intra-arterial EmboCept S® and DC Bead® effectively inhibit tumor growth of colorectal rat liver metastases. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6135-x
|
6 |
Qin Wang, Donghui Lu, Lulu Fan, Yuhuan Li, Yu Liu, Hanqing Yu, Hua Wang, Jiatao Liu, Guoping Sun. COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway. International Journal of Molecular Medicine 2018; doi: 10.3892/ijmm.2018.3936
|
7 |
|
8 |
Otilia Mårdh, Chantal Quinten, Andrew J. Amato-Gauci, Erika Duffell. Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA – descriptive analysis and estimation of 2015 baseline. Infectious Diseases 2020; 52(9): 625 doi: 10.1080/23744235.2020.1766104
|
9 |
Roberto Santambrogio, Matteo Barabino, Giovanna Scifo, Mara Costa, Marco Giovenzana, Enrico Opocher. Effect of Age (over 75 Years) on Postoperative Complications and Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2017; 21(4): 657 doi: 10.1007/s11605-016-3354-1
|
10 |
Daniel Kaemmerer, Robin Schindler, Franziska Mußbach, Uta Dahmen, Annelore Altendorf-Hofmann, Olaf Dirsch, Jörg Sänger, Stefan Schulz, Amelie Lupp. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3911-3
|
11 |
Zainul Abedin Kapacee, Mairéad G. McNamara, Nicola de Liguori Carino, Angela Lamarca, Juan W. Valle, Richard A. Hubner. Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. European Journal of Surgical Oncology 2021; 47(3): 583 doi: 10.1016/j.ejso.2020.03.210
|
12 |
Dimitrios C. Ziogas, Dionysios Papadatos-Pastos, Kiruthikah Thillai, Ippokratis Korantzis, Ruhe Chowdhury, Abid Suddle, John O’Grady, Gillian Al-Khadimi, Natalie Allen, Nigel Heaton, Paul J. Ross, Debashis Sarker. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. European Journal of Gastroenterology & Hepatology 2017; 29(1): 48 doi: 10.1097/MEG.0000000000000739
|
13 |
Saur Hajiev, Elias Allara, Leila Motedayеn Aval, Tadaaki Arizumi, Dominik Bettinger, Mario Pirisi, Lorenza Rimassa, Tiziana Pressiani, Nicola Personeni, Laura Giordano, Masatoshi Kudo, Robert Thimme, Joong-Won Park, Tamar H. Taddei, David E. Kaplan, Ramya Ramaswami, David J. Pinato, Rohini Sharma. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal of Cancer 2021; 124(2): 407 doi: 10.1038/s41416-020-01116-9
|
14 |
Melissa Yan, John Ha, Maria Aguilar, Benny Liu, Catherine T. Frenette, Taft Bhuket, Robert J. Wong. Older Patients With Hepatocellular Carcinoma Have More Advanced Disease, Lower Rates of Treatment, and Lower Survival. Journal of Clinical Gastroenterology 2017; 51(4): 378 doi: 10.1097/MCG.0000000000000590
|
15 |
Haiyong Wang, Chenyue Zhang, Huiying Chi, Zhiqiang Meng. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. International Journal of Oncology 2018; doi: 10.3892/ijo.2018.4351
|
16 |
Eric Francois, Ludovic Evesque. Encyclopedia of Gerontology and Population Aging. 2021; : 5234 doi: 10.1007/978-3-030-22009-9_777
|
17 |
A Cucchetti, C Sposito, A D Pinna, D Citterio, G Ercolani, M Flores, M Cescon, V Mazzaferro. Effect of age on survival in patients undergoing resection of hepatocellular carcinoma. Journal of British Surgery 2016; 103(2): e93 doi: 10.1002/bjs.10056
|
18 |
Jing Du, Ye Mao, Ming Liu, Yan Tie, Hai Huang, Jian Zhao, Zhongzheng Xiang, Di Luo. Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017; 8(60): 102413 doi: 10.18632/oncotarget.22061
|
19 |
Mauro Borzio, Elena Dionigi, Alessandro Vitale, Angelo Rossini, Massimo Marignani, Fabio Fornari, Susanna Vicari, Ilario De Sio, Fabio Farinati, Emanuela Bertolini, Filippo Oliveri, Gioacchino Leandro, Giampiero Francica, Mario Mitra, Barbara Omazzi, Sergio Boccia, Andrea Salmi, Anna Toldi, Rodolfo Sacco. Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in‐field multicenter cohort study. Liver International 2017; 37(8): 1184 doi: 10.1111/liv.13392
|
20 |
Nages Nagaratnam, Kujan Nagaratnam, Gary Cheuk. Geriatric Diseases. 2017; : 1 doi: 10.1007/978-3-319-32700-6_24-1
|
21 |
Antonella Cammarota, Antonio D’Alessio, Tiziana Pressiani, Lorenza Rimassa, Nicola Personeni. Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs & Aging 2021; 38(7): 579 doi: 10.1007/s40266-021-00871-5
|
22 |
Chao-Wei Lee, Kun-Ming Chan, Hsin-I Tsai, Yi-Chung Hsieh, Cheng-Yu Lin, Yung-Chia Kuo, Heng-Yuan Hsu, Ming-Chin Yu. Hepatic resection for hepatocellular carcinoma in the octogenarian: is it justified?. Aging 2019; 11(5): 1537 doi: 10.18632/aging.101854
|
23 |
Deborah A Boyle. Hepatocellular carcinoma: Implications for Asia-Pacific Oncology Nurses. Asia-Pacific Journal of Oncology Nursing 2017; 4(2): 98 doi: 10.4103/2347-5625.204497
|
24 |
Xiaofei Li, Daofu Zhang, Shan Guan, Weiwei Ye, Liwen Liu, Lianqing Lou. Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. Oncotarget 2017; 8(54): 93179 doi: 10.18632/oncotarget.21452
|
25 |
H Elalfy, T Besheer, MA El-Maksoud, K Farid, M Elegezy, AM El Nakib, MA El-Aziz, AA El-Khalek, A El-Morsy, A Elmokadem, AZ Elsamanoudy, M El-Bendary. Monocyte/granulocyte to lymphocyte ratio and the MELD score as predictors for early recurrence of hepatocellular carcinoma after trans-arterial chemoembolization. British Journal of Biomedical Science 2018; 75(4): 187 doi: 10.1080/09674845.2018.1494769
|
26 |
Shiow-Ching Shun, Yeur-Hur Lai, Hung Hung, Chien-Hung Chen, Ja-Der Liang, Yun-Jen Chou. The Role of Age in Change in Unmet Supportive Care Needs in Hepatocellular Carcinoma Patients During Transition From Hospital to Home. Cancer Nursing 2017; 40(3): 245 doi: 10.1097/NCC.0000000000000403
|
27 |
A. R. Lewis, C. Cipriano, X. Wang, R. Ward, A. Fitzpatrick, A. R. M. Scott, A. Rashed, H. Raja, A. Lamarca, R. A. Hubner, J. W. Valle, M. G. McNamara. Outcomes in patients ≥ 80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. Medical Oncology 2019; 36(10) doi: 10.1007/s12032-019-1310-0
|
28 |
Chern-Horng Lee, Tzung-Hai Yen, Sen-Yung Hsieh. Outcomes of Geriatric Patients with Hepatocellular Carcinoma. Current Oncology 2022; 29(6): 4332 doi: 10.3390/curroncol29060346
|